Sort
10,766 grants matching “checkpoint inhibitor”
Core B: Computational
$376,975Alan S Perelson · Beth Israel Deaconess Medical Center · P01 · FY2020 · AI
ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas
$376,962David M. Ashley · Duke University · R01 · FY2023 · CA
Mechanistic investigations of microbiome-driven aryl hydrocarbon receptor activity and macrophage function in pancreatic cancer.
$376,878Tracy L McGaha · University Health Network · R01 · FY2021 · CA
Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds
$376,751Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA
Role of Sirt2 in T Cell Metabolism
$376,751Sungjune Kim · H. Lee Moffitt Cancer Ctr & Res Inst · R37 · FY2022 · CA
Characterizing oncogenic function of ITCH in melanoma
$376,751Lixin Wan · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · CA
Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds
$376,751Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · CA
DNA damage signaling to immune checkpoints
$376,715Christopher J. Bakkenist · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · CA
Project 1: Targeting the PD-1 pathway in HCC
$376,652Ahmed Kaseb · University Of Tx Md Anderson Can Ctr · P50 · FY2019 · CA
Project 1: Targeting the PD-1 pathway in HCC
$376,652Ahmed Kaseb · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA
Project 1: Targeting the PD-1 pathway in HCC
$376,651Ahmed Kaseb · University Of Tx Md Anderson Can Ctr · P50 · FY2022 · CA
Project 2: Targeting STAT3 with an Oral Small Molecule to Treat HCC
$376,650David John Tweardy · University Of Tx Md Anderson Can Ctr · P50 · FY2019 · CA
Project 2: Targeting STAT3 with an Oral Small Molecule to Treat HCC
$376,649David John Tweardy · University Of Tx Md Anderson Can Ctr · P50 · FY2022 · CA
Project 2: Targeting STAT3 with an Oral Small Molecule to Treat HCC
$376,648David John Tweardy · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA
Linking Epigenetic-Therapy Induction of Inflammasome Signaling to Generation of a BRCAness Phenotype
$376,634Kenneth P Nephew · Coriell Institute For Medical Research · P50 · FY2021 · CA
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
$376,492Ann Richmond · Vanderbilt University · R01 · FY2020 · CA
Impact of Host NF-kB Signaling in Radiation Therapy
$376,455Shigeki Miyamoto · University Of Wisconsin-Madison · R01 · FY2025 · CA
Impact of Host NF-kB Signaling in Radiation Therapy
$376,455Shigeki Miyamoto · University Of Wisconsin-Madison · R01 · FY2021 · CA
RNase H2 is a novel therapeutic target in triple negative breast cancer
$376,433Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
RNase H2 is a novel therapeutic target in triple negative breast cancer
$376,433Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
$376,428Jinming Gao · Ut Southwestern Medical Center · R01 · FY2018 · CA
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
$376,428Jinming Gao · Ut Southwestern Medical Center · R01 · FY2020 · CA
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
$376,428Jinming Gao · Ut Southwestern Medical Center · R01 · FY2021 · CA
Mechanism of Mitotic Checkpoint in Mammalian Cells
$376,260Timothy Yen · Research Inst Of Fox Chase Can Ctr · R01 · FY2011 · GM
Targeting Atr to promote regeneration and functional recovery after neural injury
$376,250Yuanquan Song · Children'S Hosp Of Philadelphia · R01 · FY2021 · NS